Vaccine adjuvant expansion SPI Pharma recently launched QS-21 GH in collaboration with Q-VANT Biosciences to expand global access to advanced vaccine adjuvants, presenting a sales opportunity to source or co-develop adjuvant systems and related formulations for vaccine manufacturers.

Acquisition growth The acquisition of Elementis Specialties Inc. signals a broadened product portfolio and entry into the digestive health market, suggesting cross-selling potential to existing pharma excipient customers and new GMP-compliant supply capabilities for consumer health products.

Platform portfolio Introduction of S-Tab tablet platform and UltraBurst orally disintegrating tablet demonstrates SPI Pharma’s move into direct compression and novel dosage forms, offering sales leverage to contract manufacturers seeking robust, patent-protected excipients and tablet technologies.

Regulatory strength attainment of EXCiPACT GMP certification enhances credibility with global customers seeking compliant pharmaceutical excipients, enabling easier penetration of regulated markets and verticals requiring high-quality supply chains.

Strategic partnerships Earlier collaborations in adjuvant systems with Inimmune and ongoing efforts to develop advanced adjuvant platforms indicate opportunities to partner on development programs, co-marketing alliances, or white-label solutions for vaccine and biopharma customers.